Literature DB >> 10076754

Diaphragmatic denervation in intensive care unit patients.

H W Sander1, P B Saadeh, N Chandswang, D Greenbaum, S Chokroverty.   

Abstract

The causes of prolonged requirement for mechanical ventilation in the intensive care unit (ICU) are currently a subject of investigation. Critical illness polyneuropathy (CIP), an axonal polyneuropathy that frequently occurs with prolonged sepsis and multi-organ failure, has been cited as a frequent cause of difficulty with weaning from a ventilator. The relative contribution of diaphragmatic denervation in ICU patients with and without CIP has not been definitively determined. We reviewed 102 ventilator dependent intensive care unit (ICU) patients. Critical illness polyneuropathy (CIP) was diagnosed based upon electrodiagnostic criteria. Electrodiagnostic studies included diaphragmatic needle electromyography (EMG) to evaluate for diaphragmatic denervation. The medical charts of the patients with diaphragmatic denervation were reviewed for etiologies other than CIP for the diaphragmatic denervation. Our results suggest: 1) Respiratory impairment in ICU patients may often be unrelated to either CIP or diaphragmatic denervation; 2) Only about half of ventilator dependent CIP patients have diaphragmatic denervation; 3) Diaphragmatic denervation in ICU patients frequently may be attributable to causes other than CIP.

Entities:  

Mesh:

Year:  1999        PMID: 10076754

Source DB:  PubMed          Journal:  Electromyogr Clin Neurophysiol        ISSN: 0301-150X


  2 in total

Review 1.  The Sick and the Weak: Neuropathies/Myopathies in the Critically Ill.

Authors:  O Friedrich; M B Reid; G Van den Berghe; I Vanhorebeek; G Hermans; M M Rich; L Larsson
Journal:  Physiol Rev       Date:  2015-07       Impact factor: 37.312

2.  Does ICU-acquired paresis lengthen weaning from mechanical ventilation?

Authors:  Bernard De Jonghe; Sylvie Bastuji-Garin; Tarek Sharshar; Hervé Outin; Laurent Brochard
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.